Seres Therapeutics, Inc.
MCRB
$17.70
$1.005.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 448.44% | -- | -- | -- | -99.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 448.44% | -- | -- | -- | -99.95% |
| Cost of Revenue | 15.24% | 11.34% | -49.74% | -75.75% | -84.64% |
| Gross Profit | -13.63% | -11.34% | -138.12% | -187.09% | -47.15% |
| SG&A Expenses | -19.42% | -22.97% | -34.40% | -36.64% | -40.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.86% | -24.01% | -40.87% | -46.93% | -50.36% |
| Operating Income | 20.13% | 24.01% | -71.54% | -18.18% | 3.31% |
| Income Before Tax | 103.72% | 60.06% | 3.06% | -25.33% | -7.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 103.72% | 60.06% | 3.06% | -25.33% | -7.75% |
| Earnings from Discontinued Operations | -100.00% | 612.62% | 746.30% | 1,041.71% | 1,845.52% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 121.17% | 153.03% | 188.23% | 100.12% | 81.97% |
| EBIT | 20.13% | 24.01% | -71.54% | -18.18% | 3.31% |
| EBITDA | 19.70% | 23.90% | -81.51% | -20.16% | 3.30% |
| EPS Basic | 113.11% | 147.77% | 176.83% | 99.85% | 79.79% |
| Normalized Basic EPS | 67.67% | 44.26% | -35.76% | 8.70% | 6.76% |
| EPS Diluted | 111.50% | 147.41% | 175.48% | 99.46% | 79.80% |
| Normalized Diluted EPS | 67.70% | 44.28% | -33.93% | 9.39% | 7.28% |
| Average Basic Shares Outstanding | 19.82% | 21.02% | 22.04% | 21.40% | 14.47% |
| Average Diluted Shares Outstanding | 19.91% | 21.06% | 21.60% | 20.90% | 13.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |